{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:40:09Z","timestamp":1763005209166,"version":"3.45.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022336","name":"Esperion Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ajpc.2023.100604","type":"journal-article","created":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T08:51:50Z","timestamp":1699779110000},"page":"100604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Lipid-lowering therapy and LDL-C control for primary prevention in persons with diabetes across 90 health systems in the United States"],"prefix":"10.1016","volume":"16","author":[{"given":"Emily","family":"Decicco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Khalaf Gillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Sarnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2023.100604_bib0001","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100604_bib0002","first-page":"357","article-title":"Treatment of diabetes mellitus: the urgent need for multifactorial interventions","volume":"20","author":"Hennekens","year":"2014","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ajpc.2023.100604_bib0003","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2023.100604_bib0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ajpc.2023.100604_bib0005","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1479164113500798","article-title":"Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register","volume":"10","author":"Svensson","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.ajpc.2023.100604_bib0006","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-015-0204-5","article-title":"Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors","volume":"14","author":"Cea Soriano","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ajpc.2023.100604_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.945421","article-title":"Diabetic retinopathy predicts cardiovascular disease independently of subclinical atherosclerosis in individuals with type 2 diabetes: a prospective cohort study","volume":"9","author":"Castelblanco","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ajpc.2023.100604_bib0008","unstructured":"Centers for Disease Control and Prevention. National diabetes statistics report. Accessed April 10, 2023. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html."},{"key":"10.1016\/j.ajpc.2023.100604_bib0009","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2023.100604_bib0010","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular disease and risk management: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajpc.2023.100604_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009217.pub2","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"2013","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajpc.2023.100604_bib0012","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100604_bib0013","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/clc.22641","article-title":"Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and\/or diabetes mellitus in 2014: insights from a large US managed-care population","volume":"40","author":"Steen","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ajpc.2023.100604_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2018.02.019","article-title":"Trends and disparities in statin use and low-density lipoprotein cholesterol levels among US patients with diabetes, 1999-2014","volume":"139","author":"Gu","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ajpc.2023.100604_bib0015","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.2337\/dc20-1481","article-title":"Changes in statin use among U.S. adults with diabetes: a population-based analysis of NHANES 2011\u20132018","volume":"43","author":"Leino","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajpc.2023.100604_bib0016","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ahj.2020.04.018","article-title":"Beliefs, risk perceptions, and lipid management among patients with and without diabetes: results from the PALM registry","volume":"225","author":"Lowenstern","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.ajpc.2023.100604_bib0017","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.amjcard.2014.02.018","article-title":"Gender differences in achieving optimal lipid goals in patients with coronary artery disease","volume":"113","author":"Victor","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ajpc.2023.100604_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex differences in the use of statins in community practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ajpc.2023.100604_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.008552","article-title":"Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events: systematic review and meta-analysis","volume":"15","author":"Wang","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ajpc.2023.100604_bib0020","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamacardio.2018.1511","article-title":"Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the patient and provider assessment of lipid management registry","volume":"3","author":"Nanna","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ajpc.2023.100604_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005449","article-title":"Vulnerabilities to health disparities and statin use in the REGARDS (reasons for geographic and racial differences in stroke) study","volume":"6","author":"Schroff","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2023.100604_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014709","article-title":"Effects of race on statin prescribing for primary prevention with high atherosclerotic cardiovascular disease risk in a large healthcare system","volume":"8","author":"Dorsch","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2023.100604_bib0023","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11606-014-3102-8","article-title":"Accuracy of race, ethnicity, and language preference in an electronic health record","volume":"30","author":"Klinger","year":"2015","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.ajpc.2023.100604_bib0024","first-page":"477","article-title":"Accelerated atherosclerosis in premenopausal women with rheumatoid arthritis - 15-year follow-up","volume":"21","author":"Koren Krajnc","year":"2021","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.ajpc.2023.100604_bib0025","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avi\u00f1a-Zubieta","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajpc.2023.100604_bib0026","first-page":"201","article-title":"The impact of infection with hepatitis C virus on cardiovascular risk","volume":"10","author":"Iorga","year":"2020","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.ajpc.2023.100604_bib0027","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s12325-020-01346-6","article-title":"Psoriasis and cardiovascular risk: a comprehensive review","volume":"37","author":"Masson","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.ajpc.2023.100604_bib0028","doi-asserted-by":"crossref","first-page":"343","DOI":"10.14218\/JCTH.2017.00021","article-title":"Risk of cardiovascular disease due to chronic hepatitis C infection: a review","volume":"5","author":"Babiker","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ajpc.2023.100604_bib0029","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2023.100604_bib0030","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","article-title":"Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised, placebo-contolled trial","volume":"363","author":"McCarey","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100604_bib0031","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/art.39114","article-title":"Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: the rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study","volume":"67","author":"Rollefstad","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ajpc.2023.100604_bib0032","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.cgh.2006.03.014","article-title":"Incidence of statin hepatotoxicity in patients with hepatitis C","volume":"4","author":"Khorashadi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpc.2023.100604_bib0033","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11894-017-0584-7","article-title":"Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects","volume":"19","author":"Vargas","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.ajpc.2023.100604_bib0034","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","article-title":"Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research","volume":"6","author":"Leon","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.ajpc.2023.100604_bib0035","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2023.100604_bib0036","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2023.100604_bib0037","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2023.100604_bib0038","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100604_bib0039","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2023.100604_bib0040","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2023.100604_bib0041","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2023.100604_bib0042","unstructured":"United States Census Bureau. QuickFacts. Accessed August 29, 2023. https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/RHI225222."}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667723001459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667723001459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:37:33Z","timestamp":1763005053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667723001459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":42,"alternative-id":["S2666667723001459"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2023.100604","relation":{},"ISSN":["2666-6677"],"issn-type":[{"type":"print","value":"2666-6677"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid-lowering therapy and LDL-C control for primary prevention in persons with diabetes across 90 health systems in the United States","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2023.100604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100604"}}